Faculty Member


Rudolf Jaenisch

Rudolf Jaenisch

Founding Member, Whitehead Institute

Professor of Biology, MIT




We are focused on understanding the epigenetic regulation of gene expression in mammalian development and diseases, including Parkinson’s, autism spectrum disorders, and Rett and Fragile X syndromes. We have used patient-derived induced pluripotent stem cells to develop sophisticated models of conditions, such as Alzheimer’s disease and diabetes.

Rudolf Jaenisch, a Whitehead Institute Founding Member and National Medal of Science recipient, focuses on understanding epigenetic regulation of gene expression (the biological mechanisms that affect how genetic information is converted into cell structures but that don’t alter the genes in the process). Most recently, this work has led to major advances in our understanding of embryonic stem cells and “induced pluripotent stem” (IPS) cells, which appear identical to embryonic stem cells but can be created from adult cells without using an egg.

In 2007, the Jaenisch lab was one of three labs worldwide that reported successfully taking cells from mouse tails and reprogramming them into IPS cells, by over-expressing four master gene regulators. Later that year, the lab followed up by further manipulating IPS cells to treat sickle-cell anemia in mice, the first proof in principle of therapeutic use of such cells. In 2008, the lab reported that neurons derived from IPS cells successfully integrated into fetal mouse brains and reduced symptoms in a Parkinson’s disease rat model. In another experiment, researchers demonstrated that fully mature, differentiated mouse B cells can be reprogrammed to IPS cells.

Researchers are now studying ways to optimize the creation of IPS cells, including finding alternatives to the potentially cancer-causing retroviruses used to transform the adult cells into IPS cells.

In the long run, IPS cells offer major promise for use in regenerative medicine, potentially supporting the growth of healthy cells and tissues derived from a patient’s own cells. Closer in time, the cells will allow scientists to transfer complex human diseases into Petri dishes for study, taking a first step toward analyzing the conditions and developing therapies.

In addition to its stem cell work, Jaenisch’s lab is investigating epigenetic mechanisms for certain types of cancer and for brain development, studying how conditions such as Rett Syndrome occur.

Jaenisch received his doctorate in medicine from the University of Munich in 1967. Before coming to Whitehead, he was head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg. He has coauthored more than 375 research papers and has received numerous prizes and recognitions, including an appointment to the National Academy of Sciences in 2003.

Selected Achievements

  • Created the first transgenic animal model
  • First experiment showing that therapeutic cloning could correct genetic defects in mice
  • Member, National Academy of Sciences
  • Member, National Academy of Medicine
  • Fellow, American Academy of Arts and Sciences
  • Boehringer Mannheim Molecular Bioanalytics Prize (1996)
  • First Peter Gruber Foundation Award in Genetics (2001)
  • Robert Koch Prize for Excellence in Scientific Achievement (2002)
  • Brupracher Foundation Cancer Award (2003)
  • Vilcek Prize (2007)
  • Meira and Shaul G. Massry Prize (2008)
  • Cozzarelli Prize from the Proceedings of the National Academy of Sciences (2009)
  • Ernst Schering Prize (2009)
  • Wolf Prize in Medicine (2011)
  • President's National Medal of Science, 2010 (awarded in 2011)
  • Otto Warburg Medal (2014)
  • President, International Society for Stem Cell Research, 2014-2015

© Whitehead Institute for Biomedical Research              455 Main Street          Cambridge, MA 02142